Modeling of randomized hepatitis C vaccine trials: Bridging the gap between controlled human infection models and real-word testing.

ABSTRACT: Global elimination of chronic hepatitis C (CHC) remains difficult without an effective vaccine. Since injection drug use is the leading cause of hepatitis C virus (HCV) transmission in Western Europe and North America, people who inject drugs (PWID) are an important population for testing HCV vaccine effectiveness in randomized-clinical trials (RCTs). However, RCTs in PWID are inherently challenging. To accelerate vaccine development, controlled human infection (CHI) models have been suggested as a means to identify effective vaccines. To bridge the gap between CHI models and real-world testing, we developed an agent-based model simulating a two-dose vaccine to prevent CHC in PWID, representing 32,000 PWID in metropolitan Chicago and accounting for networks and HCV infections. We ran 500 t

SUBMITTER: Mackesy-Amiti ME 

PROVIDER: S-EPMC11704953 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature